Dr Hannah Kirk
Chief Research Officer
Dr Kirk is a developmental neuroscientist who completed her PhD at Monash University in the Institute of Cognitive and Clinical Neurosciences. Dr Kirk was one of the inventors of the TALI system and conducted the first clinical trial to evaluate the benefits of this Technology.
Dr Kirk has published 10 peer-reviewed articles in highly regarded journals, presented at both national and international conferences and been the recipient of several research and industry based awards. She currently retains an Adjunct Research Fellowship in the Institute of Cognitive and Clinical Neurosciences at Monash University.
As part of the TALI Health team, Dr Kirk’s goal is to design scientifically driven tasks that benefit cognition and behaviour in both typically developing children and clinical populations.
Ms Magda Klapakis
Ms Klapakis has been with Avexa since its inception and brings over 25 year’s of professional experience including significant engagement in the healthcare industry. She started her career with National Mutual Holdings (NMH) in a range of senior financial positions. During that time she was seconded for twelve months to the NSP Buck to set up their Finance Department, before returning to develop and maintain the NMH Forecast Model that was used in the successful demutualisation and subsequent listing of the company on the ASX as AXA Asia Pacific.
Magda moved into the Healthcare services sector in 2001 when she joined Endeavour Healthcare as their Finance Manager. She started working for listed biotech entity Amrad Corporation (later renamed Zenyth Therapeutics) in early 2003 before joining Avexa.
Mr Lee Mitchell
Mr Mitchell was previously a partner in a premier mid‑tier law firm in their corporate group. He remains a qualified solicitor practising principally in corporate and commercial law advising on corporate and securities regulation, capital raisings, formulation and implementation of mergers and acquisitions, corporate governance and secretarial matters.